Rubicon Research Ltd Share Price

Pharmaceuticals - Indian - FormulationsNSE
₹1,718.70
-3.60-0.21% (1D)
As on 20 Nov 2026 at 15:58
As of 20 Nov 2026 at 15:58, Rubicon Research Ltd is trading at ₹1,718.70. The 52-week range stands at ₹609.25–₹1,899.00, with a market cap of ₹28.46 thousand crore. At a P/E of 113.71 and a dividend yield of 0.09%, it is a large-cap stock in the Pharmaceuticals sector.

RUBICON Price Chart

Market Cap
₹28.46K Cr
PE Ratio
113.71
ROCE
18.99%

Rubicon Research Ltd Performance

Rubicon Research Ltd Fundamentals

Know More
Market Cap₹28.46K Cr
ROE16.86%
P/E Ratio (TTM)113.71
EPS (TTM)₹15.12
P/B Ratio19.17
Dividend Yield0.09%
Industry P/E91.72
Book Value₹89.68
Debt to Equity0.28
Face Value₹1

Rubicon Research Ltd Shareholding Pattern

Know More
Promoter51.3%
Foreign Institutions9%
Mutual Funds13.8%
Domestic Institutions0.2%
Public25.8%

Rubicon Research Ltd Financial Statements

Know More
No data for this view.

Rubicon Research Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Rubicon Research

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'. A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra. The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011. In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limited on slump sale as a going concern. In FY 2024, the Company acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. It commenced the manufacturing of nasal products at Ambernath Plant in 2024. The Company has acquired Pithampur Manufacturing Facility from Alkem Laboratories Ltd in 2025. The Company came up with its initial public offering of 28,405,841 equity shares of face value of Re 1 each, by raising funds aggregating to Rs 1378 crores, comprising a fresh issue of 10,313,058 equity shares aggregating to Rs 500 crores and the offer for sale of 18,092,783 equity shares aggregating to Rs 878 crores on October 13, 2025. The Company acquired 85% stake in Arinna Lifesciences Limited at Pithampur in April 2026.

Parent Organisation—
Founded1999
Managing DirectorPratibha Pilgaonkar
NSE SymbolRUBICON

Rubicon Research Ltd Resistance and Support levels

R31,800.37R21,764.34R11,742.09S11,670.04S21,647.79S31,611.771,718.70

Rubicon Research Ltd Technicals

Current Price
₹1,718.70 ₹3.60 (-0.21%)
Bearish
0
Bullish
12
  • 20 Day3.3%
  • 50 Day5.2%
  • 100 Day11.1%
  • 200 Day32.8%

Rubicon Research Ltd Latest News

View More
27 OCT 2026 | Tuesday
Rubicon Research to announce financial results for the quarter and half year ended September 30, 2026
09 OCT 2026 | Friday
Rubicon Research confirms MUFG Intime India compliance with SEBI regulations
08 OCT 2026 | Thursday
Rubicon Research Limited’s committee granted 7,200 shares via employee stock options
28 SEPT 2026 | Monday
Rubicon Research closes securities trading window ahead of financial results release
14 AUG 2026 | Friday
Rubicon Research appoints Rohit Saraogi as CFO, with Nitin Jajodia transitioning to Chief Commercial Officer
07 AUG 2026 | Friday
Rubicon Research Limited to review quarterly financial results at August board meeting
03 AUG 2026 | Monday
Rubicon’s report shows 5% of products sourced from MSMEs, up from 2% previously
21 JUL 2026 | Tuesday
Rubicon Research schedules AGM
20 JUL 2026 | Monday
Rubicon Research board approves merger with subsidiary
20 JUL 2026 | Monday
Rubicon Research allots 1.49 lakh equity shares under ESOS

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Annual ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Rubicon Research Ltd is ₹1,718.70 as of 20 Nov 2026 at 15:58.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now